Private health tests marketed to symptom-free people in the UK "lack evidence of benefit," according to an investigation. Researchers found that the "vast array" of screening tests on offer can cost up to £14,000, and some firms inaccurately claim they can extend life "despite a lack of evidence" that this is the case.
Study examines 50 firms' offerings
The study, published in the journal BMJ Open, was led by a team from the University of St Andrews. Researchers examined information on the websites of 50 firms selling commercial tests for people without symptoms, then compared what was on offer to the NHS.
All the tests offered by private companies were either not recommended or offered by the NHS, the study found. These included blood tests (such as full blood counts, liver function, genetic testing), stool, saliva and urine tests (including for protein, cortisol and gut microbiome), whole body MRI scans and other imaging or breast investigations, as well as body "packages."
Prices and specific findings
Prices ranged from £6.99 to £14,000 for "platinum" services. Researchers said that contrary to NHS advice and guidelines, 12 firms offered breast mammograms to normal-risk, symptomless women under the age of 50, while 45 offered to test lipids and Hb1ac (for fasting blood glucose) to healthy adults under 40.
Overall, 31 firms offered follicle-stimulating hormone tests to all women over 45, and others offered tests for hidden blood in the stool to adults under 50. Some 13 firms also offered breast exams, while nine offered pelvic exams to people not displaying concerning symptoms.
Claims and potential harms
Overall, 36 of the 50 vendors made claims for earlier diagnosis and better outcomes, 48 made claims for better knowledge of health, and 16 made claims for living longer. Most (70%) vendors did not explain the limitations of testing or potential harms, the study found, and many still asked consumers to involve their own NHS doctor once they got their results.
The researchers said: "While it is possible that appropriate, high-quality health testing bought directly by consumers could fill gaps in NHS service delivery, it is also possible that poor quality screening tests will negatively impact citizens through false positives (false alarms), false negatives (false reassurance) and loss of personal resources with little or no value gained by individuals."
"NHS primary care is already experiencing the impacts of follow-up of test results initiated by consumers rather than the NHS," they added.
Calls for tighter regulation
In conclusion, the team called for tighter regulation of the market, saying: "UK consumers are sold multiple screening tests that lack evidence of benefit. There are substantive gaps in regulation. Given the growth in this sector, urgent, co-ordinated actions across regulators are required to protect consumers from poor value or harmful tests, and limit negative impact to the NHS."
Dr Stephen Harden, president of the Royal College of Radiologists, said: "This study reflects our concerns about elective medical scans for people with no symptoms, outside of established national screening programmes. These scans can sound reassuring, but for people without symptoms they can do more harm than good."
"They can pick up harmless abnormalities that would never have caused a health problem, but that lead to further tests, unnecessary treatment and avoidable anxiety. There is no medical reason to get a scan as a preventative measure unless referred by a doctor to investigate symptoms," he added.
"We encourage people to attend NHS screening programmes they are eligible for and speak to their GP if they have symptoms or concerns about their health."